[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oric Pharmaceuticals Inc (ORIC)

Oric Pharmaceuticals Inc (ORIC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC : 9.47 (+0.32%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

NEW YORK , April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC).  Such investors are...

ORIC : 9.47 (+0.32%)
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (“Oric” or “the Company”)...

ORIC : 9.47 (+0.32%)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC : 9.47 (+0.32%)
Stocks Settle Higher on Hopes for Conclusion to Iran War

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up +0.72%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.18%. June E-mini...

ALK : 38.60 (+0.76%)
MPC : 241.43 (-0.16%)
SNDK : 1,098.69 (+3.24%)
HL : 17.84 (+2.12%)
CDE : 17.54 (+1.21%)
LITE : 882.04 (+2.76%)
OXY : 59.93 (-1.37%)
NCNO : 17.01 (-2.58%)
GLW : 152.82 (+0.61%)
FANG : 205.45 (+0.06%)
STX : 678.39 (+5.45%)
WDC : 434.29 (+5.22%)
Stocks Climb on War-End Optimism

The S&P 500 Index ($SPX ) (SPY ) today is up +0.97%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.86%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.45%. June E-mini S&P futures (ESM26...

ALK : 38.60 (+0.76%)
MPC : 241.43 (-0.16%)
SNDK : 1,098.69 (+3.24%)
HL : 17.84 (+2.12%)
CDE : 17.54 (+1.21%)
LITE : 882.04 (+2.76%)
OXY : 59.93 (-1.37%)
NCNO : 17.01 (-2.58%)
GLW : 152.82 (+0.61%)
FANG : 205.45 (+0.06%)
STX : 678.39 (+5.45%)
WDC : 434.29 (+5.22%)
Stocks Rally on Optimism that the War in Iran is Near a Conclusion

The S&P 500 Index ($SPX ) (SPY ) today is up +0.52%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.43%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.68%. June E-mini S&P futures (ESM26...

AMAT : 389.49 (+1.80%)
B : 38.97 (+1.35%)
SNDK : 1,098.69 (+3.24%)
HL : 17.84 (+2.12%)
CDE : 17.54 (+1.21%)
$IUXX : 27,180.25 (-0.02%)
ASML : 1,400.29 (+0.45%)
ZNM26 : 110-180 (+0.18%)
NCNO : 17.01 (-2.58%)
ESM26 : 7,175.50 (+0.10%)
STX : 678.39 (+5.45%)
WDC : 434.29 (+5.22%)
ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, with initiation expected in 1H 2026 ...

ORIC : 9.47 (+0.32%)
ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC : 9.47 (+0.32%)
ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC : 9.47 (+0.32%)

Barchart Exclusives

Kinder Morgan Stock Is Normally Boring, but the Iran War Just Created an Exciting Short-Term Trade in KMI
Although KMI stock is probably best known as a stable dividend play, there’s a chance for bullish speculators to scalp a quick profit. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.